PTH and hypoparathyroidism: Participants treated with TransCon PTH also achieved normal mean serum calcium, serum phosphate, and urine calcium, and demonstrated improved HRQoL over 26 weeks of treatment.(13) The primary objective of the phase 3, randomized, double‐blind, placebo‐controlled PaTHway trial was to assess the treatment effect of once‐daily TransCon PTH on serum calcium levels and therapeutic doses of active vitamin D (ie, calcitriol or alfacalcidol) and elemental calcium in adults with hypoparathyroidism over 26 weeks.